Assess whether the primary endpoint will survive FDA scrutiny (e04611)

SITUATION A safety team sitting on a new disproportionate signal cannot treat an FAERS cluster in a demographic the trials under-enrolled as incidental context on CMC comparability package for a site change. CMC change-control owner must close the primary endpoint will from that extract under Pharma & Life Sciences / Clinical and Evidence Strategy.

DECISION CMC change-control owner in a safety team sitting on a new disproportionate signal must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using CMC comparability package for a site change after an FAERS cluster in a demographic the trials under-enrolled.

HYPOTHESES TO TEST 1. CMC comparability package for a site change reads as Proceed under protocol once an FAERS cluster in a demographic the trials under-enrolled is lined up to the same Pharma & Life Sciences population. 2. CMC comparability package for a site change is closer to Pause the pathway after an FAERS cluster in a demographic the trials under-enrolled; Proceed under protocol would over-claim this Clinical and Evidence Strategy extract. 3. Escalate safety review is still live in CMC comparability package for a site change for CMC change-control owner in a safety team sitting on a new disproportionate signal. 4. CMC comparability package for a site change is missing the fact CMC change-control owner needs after an FAERS cluster in a demographic the trials under-enrolled; stop this Pharma & Life Sciences close.

ANALYSIS REQUIRED 1. Check whether CMC comparability package for a site change supports the labeled claim CMC change-control owner would keep. 2. Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal. 3. Trace CMC, labeling, or pharmacovigilance facts in CMC comparability package for a site change after an FAERS cluster in a demographic the trials under-enrolled. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read CMC comparability package for a site change against an FAERS cluster in a demographic the trials under-enrolled and write the one fact that would move the primary endpoint will for CMC change-control owner.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (CMC comparability package for a site change after an FAERS cluster in a demographic the trials under-enrolled). The follow-on Clinical and Evidence Strategy action is what CMC change-control owner does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on the primary endpoint will, then the evidence in CMC comparability package for a site change, then the action for CMC change-control owner - Hypothesis scorecard against CMC comparability package for a site change: supported / rejected / untestable - Owner and next date for CMC change-control owner in a safety team sitting on a new disproportionate signal - What changes the primary endpoint will if an FAERS cluster in a demographic the trials under-enrolled is later withdrawn